SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated March 11, 2025, reports a transaction in the company's own shares. The filing covers share repurchase activity executed on March 10, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share buybacks rather than comprehensive financial statements. Key metrics for the transaction on March 10, 2025, include:
- Shares Purchased: 508,000 ordinary shares.
- Price Range: Lowest price paid was 1,532.50 GBp; highest price paid was 1,559.50 GBp.
- Average Price: Volume-weighted average price paid was 1,548.49 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 176,607,345 ordinary shares in treasury.
- Shares in Issue: 4,138,581,996 ordinary shares (excluding treasury shares).
- Voting Rights: Total voting rights stand at 4,138,581,996.
Material Changes and Program Progress
Since the commencement of the current buyback agreement on February 24, 2025, the Company has purchased an aggregate of 7,537,042 ordinary shares. The March 10 transaction represents a continuation of this existing program. No other material changes to the company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk factors" section of GSK's 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total number of treasury shares held (176,607,345) against the company's latest capital structure disclosures.
- Confirm the remaining authorization under the buyback program initiated on February 24, 2025.
- Review the 2024 Annual Report on Form 20-F for the full list of risk factors referenced in the cautionary statement.
- Check subsequent filings for updates on the aggregate number of shares purchased under the ongoing program.